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In cancer screening, it is essential to undertake effective screening with appropriate method-
ology, which should be supported by evidence of a reduced mortality rate. At present, mam-
mography is the only method for breast cancer screening with such evidence. However,
mammography does not achieve sufﬁcient accuracy in breasts with high density at ages
below 50. Although ultrasonography achieves better accuracy in Breast Cancer detection
even in dense breasts, the effectiveness has not been veriﬁed. We have planned a random-
ized controlled trial to assess the effectiveness of ultrasonography in women aged 40–49,
with a design to study 50 000 women with mammography and ultrasonography (intervention
group), and 50 000 controls with mammography only (control group). The participants are
scheduled to take second round screening with the same modality 2 years on. The primary
endpoints are sensitivity and speciﬁcity, and the secondary endpoint is the rate of advanced
breast cancers.
Key words: breast cancer screening – mammography – ultrasonography – randomized controlled
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INTRODUCTION
Breast cancer is one of the most common cancers worldwide
(1). The age-standardized incidence rate is the ﬁrst among all
female cancers, and it is continuously increasing in Japan
(2,3), although Japan has a lower risk of breast cancer in com-
parison with Western countries. The incidence peaks at ages
45–49, and the mortality peaks at ages 55–59 in Japan (2). In
breast cancer screening, it is essential to undertake effective
screening with appropriate methodology. Effective screening
should be supported by evidence of a reduced mortality rate.
At present, mammography (MG) is the only method for breast
cancer screening that has such evidence. However, MG does
not achieve sufﬁcient screening accuracy in breasts with high
mammary gland density. Dense breasts are common at ages
below 50 and are more common in Japanese populations than
in Western populations (4). As the US Preventive Services
Task Force (USPSTF) recommends against routine screen MG
in women aged 40–49 years, the issue of breast imaging to
screen women aged 40–49 still remains unclear (5).
Since ultrasonography (US) achieves better accuracy in
breast cancer detection even in dense breasts (6)a n ds u p -
plemental screening US has the potential to depict early
breast cancers not seen on MG (6–8), several single-
institution observational studies in screening setting began.
As mentioned in the WHO guidelines, ‘population-based
cancer screening’ conducted as a public health program
should be undertaken only when there is evidence of a
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nology in population-based breast cancer screening, it is
essential to evaluate the effectiveness. However, randomized
controlled trials (RCTs), cohort studies or case–control
studies have not been completed to assess the efﬁcacy of
screening US to reduce breast cancer mortality, and the
effectiveness has not been veriﬁed.
Therefore, we have planned an RCT to assess effectiveness
of screening US for breast cancer, the Japan Strategic
Anti-cancer Randomized Trial (J-START) in 2006. The
deﬁned study population is women aged 40–49 years, because
this is the age range at which breast cancer peaks in Japan (2)
and because a high percentage of Japanese women aged 40s
have dense breast. This is a large-scale controlled trial,
designed to study 50 000 women with MG and US (interven-
tion group) and 50 000 controls with MG only (control group).
The primary endpoints of this trial are the inter-group com-
parisons of the sensitivity and speciﬁcity, and the secondary
endpoint is the inter-group comparison of the accumulated
incidence rate of advanced breast cancer during the follow-up
period. The most important index in the evaluation of the
effectiveness of cancer screening is the mortality rate from
the cancer in question in the target population. However, in
view of the natural history of breast cancer, the 4-year period
scheduled in the strategic study grant is too short to observe a
signiﬁcant inter-group difference. Although the rate of
advanced breast cancer could be a surrogate for mortality
reduction, it is necessary to have a system that has the long-
term follow-up of the survival status of individuals even after
the completion of the strategic study, J-START.
This study may have several limitations. First, the screening
interval is 2 years, despite evidence that screening MG at age
40–49 years is more effective with annual screening. The
recent USPSTF, however, recommends biannual MG screen-
ing in view of reducing ‘harm’, i.e. higher recall rate at age
40–49 years (5). Secondly, the study population, which is so
different from that in Western countries, may limit the gener-
alization of study outcomes. Most countries in Asia, however,
demonstrate the similar trend of breast cancer incidence as
observed in Japan; therefore, this trial may inﬂuence their
health strategy against breast cancer. Nevertheless, for women
aged 40–49 years even in Western countries, there is a limit-
ation of MG screening as the USPSTF recommends against
the routine use of screening MG for this age group. Thirdly,
the study may be underpowered to provide follow-up data on
breast cancer deaths because of the low breast cancer risk of
native Japanese women. In this context, as much as 100 000
women are targeted in this trial to ensure the statistical power
be sufﬁcient enough in comparison between the two groups.
PROTOCOL DIGEST OF THE STUDY
PURPOSE
The aim of this study is to assess the effectiveness of screen-
ing US for breast cancer in women aged 40–49 (Fig. 1).
STUDY SETTING
This study is a multi-institutional prospective RCT, with 42
participating centers in 23 prefectures in Japan as of 31
March 2011.
ENDPOINTS
The primary endpoints of this trial are sensitivity and speci-
ﬁcity, based on the data of each incremental cancer detection
rate, false-positives and false-negatives should be forthcom-
ing in 2 years. The secondary endpoint is the rate of
advanced breast cancers, as this has been demonstrated in
the screening MG RCTs to be a surrogate for mortality
reduction (10).
ELIGIBILITY CRITERIA
Inclusion criteria are as follows:
(i) women aged 40–49 years when registered;
(ii) women signed the informed consent to participate in
the study.
Exclusion criteria are as follows:
(i) women with a history of breast cancer;
(ii) women with a history of malignant disease other than
breast cancer within 5 years;
(iii) women in severe condition, who are not expected to
live for 5 years.
TREATMENT METHODS
PATIENT ASSIGNMENTS
Each participating center conﬁrms the participants’ eligibility
and screening methods are assigned according to the random
Figure 1. J-START study design. MG, mammography; US,
ultrasonography.
276 RCT on ultrasonography in breast cancer screeningnumber provided by the Japan Clinical Research Supporting
Unit (J-CRSU) Data Center. Cluster randomization is also
used in some institutions.
SCREENING METHOD AND ASSESSMENT
For the intervention arm, US and MG are performed at the
same time. For the control arm, MG is performed. The tech-
nologists and the physicians involved in this trial are asked
to ﬁnish 2-day, 16-h education program for the standardiz-
ation of US screening for breast cancer. Regarding the pro-
cedure in screening with US, the handheld US is performed
by a technologist or by a physician, and later, the US image
is interpreted by a physician. An interpretation of MG is per-
formed by a physician who is not regulated to be the same
doctor interpreting US image or not, although the categoriz-
ation of the two modalities are deﬁned separately in the pro-
tocol. The ﬁndings of MG and/or US are subsequently
evaluated by authorized screeners and are classiﬁed into ﬁve
categories as follows: Category 1, negative; Category 2,
benign ﬁnding(s); Category 3, probably benign ﬁnding(s);
Category 4, suspicious abnormality; and Category 5, malig-
nancy. The women who are rated in Category 3 or higher by
the MG and/or US are referred for further diagnostic
examinations.
STATISTICAL ANALYSIS
The sample size was calculated on the hypothesis that
adjunct US is expected to improve sensitivity of the inter-
vention group compared with the control group. Our pre-
vious data demonstrated the lower sensitivity of MG
screening, 71% in women aged 40–49, when compared with
those in women aged 50–59 and 60–69, 85 and 86%,
respectively (11). Assuming that the sensitivity increases
from 71 to 86% by adding US to MG, 42 500 subjects for
each arm is needed to make it 5% statistical signiﬁcance
(two-sided) with 80% power. Thus, the number of 100 000
subjects (two arms combined) is set to be a targeted sample
size to verify the primary endpoint, a sensitivity improve-
ment in the intervention group when compared with the
control group.
FOLLOW-UP PERIOD
The participants are invited to be screened 2 years after the
ﬁrst recruitment or asked to answer questionnaires of health
status, history of receiving other screening program, inci-
dence of breast cancer, and history of hospital consultation
with any breast symptoms within 2 years. For evaluating the
actual evidence of a reduced mortality rate of the interven-
tion group compared with the control group, there must be
needed to establish follow-up strategies for a long time
period and systematic, nationwide population-based cancer
registries.
REGISTRATION OF THE PROTOCOL
The J-START was registered on the University Hospital
Medical Information Network Clinical Trial Registration
(UMIN-CTR), Japan (registration number:
UMIN000000757), on 2007. Details are available at the
following address: https://upload.umin.ac.jp/cgi-open-bin/
ctr/ctr.cgi?function¼brows&action¼brows&type¼summary
&recptno¼R000000910&language¼E.
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